Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States.
FAIL · Does not pass the screen
3.13 USD
Price as of 28 May 2026Daily close, not a live quoteLast reviewed 157 days ago
Screened 2026-05-28 · the tape above runs as of 14:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price3.13 USD
Fair value3.28
Ethical score64.7/100
Our investment reviews on this name
2026-07-02Read Markup3.130.0% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Esperion Therapeutics, Inc. holds its Markup at $3.13. The statistical read favours the sellers, held for 18 days.
As held on the ledger · 2026-05-28
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 18 days
Price at the screen
$3.13
Valuation
0.00 trailing · 12.16 forward price to earnings
Values screen
FAIL· score 64.7
Beta
1.06
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
54.14%
Below 33%
Interest-bearing debt is 54.1% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
66.12%
Below 49%
Money owed to the company is 66.1% of assets, above the 49% limit.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Esperion Therapeutics,'s business is in a permissible area, but its interest-bearing debt is about 54% of the company, well over the ~33% line, so it does not pass on the financial screens. Its receivables are also high.
Read as at 2026-10-31. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ESPR's ethical verdict changes
Today ESPR does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-05-28 screen. The gold marker is the market price at the same screen. A 4.8% margin of safety to the base estimate.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ESPR trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-29Markup$3.13+0.0%Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. Over the past year the shares are up 158%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (4 analysts) rates it none, with a mean price target of $3.
2026-10-16Markup$3.13+0.0%Entry 7
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. Over the past year the shares are up 158%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (4 analysts) rates it none, with a mean price target of $3.
2026-10-02Markup$3.13-1.6%Entry 6
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 1.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. Over the past year the shares are up 158%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (4 analysts) rates it none, with a mean price target of $3.
2026-08-28Markup$3.18+0.0%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. Over the past year the shares are up 158%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (4 analysts) rates it none, with a mean price target of $3.
2026-07-28Markup$3.18+1.6%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. Over the past year the shares are up 158%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (4 analysts) rates it none, with a mean price target of $3.
2026-07-18Markup$3.13+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading bearish. Over the past year the shares are up 158%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (4 analysts) rates it none, with a mean price target of $3.
2026-07-03Markup$3.13+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (65). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markup$3.13Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (65). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.